Comparison of the efficacy of neoadjuvant chemotherapy with FLOT regimen and adjuvant chemotherapy with XELOX/FOLFOX regimen in patients with locally advanced gastric cancer: A retrospective study
- Authors: Semenov N.N.1, Izrailov R.E.1, Semenov N.E.1, Zhukova L.G.1, Feoktistova P.S.1, Matveychuk D.A.1, Khatkov I.E.1,2
-
Affiliations:
- Loginov Moscow Clinical Scientific Center
- Russian University of Medicine
- Issue: Vol 26, No 3 (2024)
- Pages: 269-275
- Section: Articles
- URL: https://bakhtiniada.ru/1815-1434/article/view/275817
- DOI: https://doi.org/10.26442/18151434.2024.3.202981
- ID: 275817
Cite item
Full Text
Abstract
Background. To date, there is no consensus on the preferred sequence of combined treatment in patients with locally advanced gastric cancer (perioperative chemotherapy – POCT or primary surgical treatment). No direct comparison of these approaches had been conducted before.
Aim. To compare, in retrospective analysis, 3-year relapse-free (RFS) and overall survival (OS) in patients receiving POCT FLOT or adjuvant chemotherapy XELOX/FOLFOX for locally advanced gastric cancer.
Materials and methods. The assessment included 153 patients who underwent POCT FLOT and 171 patients who underwent surgical treatment at the first stage. When evaluating the initial characteristics, it was shown that patients with ECOG (The Eastern Cooperative Oncology Group) stage 1-2, clinical stage cT4a-b, cN2-3 and Bormann type 4 to were significantly more common in the POCT group. Morphological characteristics: grade, presence of signet cell carcinoma, HER2/neu overexpression, microsatellite instability, sensitivity to immunotherapy (Combined Positive Score) didn't differ.
Results. With a median follow-up of 40 months, it was shown that the long-term results assessed in all included patients were better in the group with primary surgical treatment: 3-year RFS was 55 and 40% (risk ratio – RR 1.33, 95% confidence interval – CI 1.08–1.64; р=0.007). 3-year OS was 68 and 56% (RR 1.36, 95% CI 1.02–1.8; р=0.04), respectively. However, when evaluating patients who received surgical treatment in the POCT group (n=121, 79%), the results did not differ: 3-year RFS 55 and 50% (RR 0.9, 95% CI 0.71–1.16; р=0.97), 3-year OS 68 and 63% (RR 1.1, 95% CI 0.84–1.59; р=0.97). Insufficient volume of adjuvant chemotherapy (<75% of the dose) significantly worsened long-term results (3-year OS 43 and 71%; p=0.002).
Conclusion. The obtained data of a retrospective analysis did not reveal the advantages of any of the approaches provided that the surgical stage was performed in patients receiving POCT. To obtain more objective results, it is necessary to conduct randomized multicenter studies in the high volume centers, providing the necessary sample capacity, quality of diagnosis and treatment. Thus, the design of future studies should be based on the hypothesis of non-inferiority, which inevitably entails a significant increase in the required number of observations to obtain reliable sampling power.
Full Text
##article.viewOnOriginalSite##About the authors
Nikolay N. Semenov
Loginov Moscow Clinical Scientific Center
Email: nn.semenov@mknc.ru
ORCID iD: 0000-0003-4691-7490
D. Sci. (Med.)
Russian Federation, MoscowRoman E. Izrailov
Loginov Moscow Clinical Scientific Center
Email: r.izrailov@mknc.ru
ORCID iD: 0000-0002-1935-869X
D. Sci. (Med.)
Russian Federation, MoscowNikolay E. Semenov
Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: n.semenov@mknc.ru
ORCID iD: 0000-0001-5543-199X
Cand. Sci. (Med.)
Russian Federation, MoscowLiudmila G. Zhukova
Loginov Moscow Clinical Scientific Center
Email: krisman03@gmail.com
ORCID iD: 0000-0003-4848-6938
D. Sci. (Med.), Corr. Memb. RAS
Russian Federation, MoscowPolina S. Feoktistova
Loginov Moscow Clinical Scientific Center
Email: krisman03@gmail.com
ORCID iD: 0000-0002-0340-7119
SPIN-code: 9638-4788
Cand. Sci. (Med.)
Russian Federation, MoscowDanila A. Matveychuk
Loginov Moscow Clinical Scientific Center
Email: d.matvechuk@mknc.ru
ORCID iD: 0000-0002-8801-4903
surgeon oncologist
Russian Federation, MoscowIgor E. Khatkov
Loginov Moscow Clinical Scientific Center; Russian University of Medicine
Email: m.kirukova@mknc.ru
ORCID iD: 0000-0002-4088-8118
D. Sci. (Med.), Prof., Acad. RAS, Loginov Moscow Clinical Scientific Center, Russian University of Medicine
Russian Federation, Moscow; MoscowReferences
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20. doi: 10.1056/NEJMoa055531
- Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-57. doi: 10.1016/S0140-6736(18)32557-1
- Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4
- Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-20. doi: 10.1056/NEJMoa072252
- Fuse N, Bando H, Chin K, et al. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: A phase II study. Gastric Cancer. 2017;20(2):332-40. doi: 10.1007/s10120-016-0606-4
- Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery and its limits for radicality. World J Surg. 1987;11(4):418-26. PMID: 3630186
- Nakajima T, Nishi M. Surgery and adjuvant chemotherapy for gastric cancer. Hepatogastroenterology. 1989;36(2):79-85. PMID: 2659483
- Sasako M, Sano T, Katai H, Maruyama K. Radical surgery. In: Sugimura T, Sasako M, eds. Gastric cancer. Oxford: Oxford University Press, 1997.
- Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11): 2069-77. doi: 10.1200/JCO.2004.08.026
- Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79(9-10):1522-30. PMID: 10188901
- Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908-14. PMID: 10089184
- Son SY, Hur H, Hyung WJ, et al. Korean Laparoendoscopic Gastrointestinal Surgery Study (KLASS) Group. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. J AMA Surg. 2022;157(10):879-86. doi: 10.1001/jamasurg.2022.2749
- Huang C, Liu H, Hu Y, et al. Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: Five-year outcomes from the CLASS-01 randomized clinical trial. JAMA Surg. 2022;157(1):9-17. doi: 10.1001/jamasurg.2021.5104
- Etoh T, Ohyama T, Sakuramoto S, et al. Japanese Laparoscopic Surgery Study Group (JLSSG). Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: The JLSSG0901 randomized clinical trial. JAMA Surg. 2023;158(5):445-54. doi: 10.1001/jamasurg.2023.0096
- Semenov N, Dalgatov K, Izrailov R, Zhukova L. FLOT compared to FOLFOX/XELOX as a neoadjuvant chemotherapy in locally advanced gastric cancer. Experience of two clinics. J Clin Oncol. 2024;42 (Suppl. 3):361. doi: 10.1200/JCO.2024.42.3_suppl.361
- Рак желудка. Клинические рекомендации. Режим доступа: https://cr.minzdrav.gov.ru/schema/574_1. Ссылка активна на 05.07.2024 [Rak zheludka. Klinicheskie rekomendatsii. Available at: https://cr.minzdrav.gov.ru/schema/574_1. Accessed: 05.07.2024 (in Russian)].
Supplementary files
